ravulizumab
Sponsor Astrazeneca PLC · listed as AZN
ravulizumab is a drug asset sponsored by Astrazeneca PLC, listed as AZN. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Aug 17, 2027 (day precision, medium confidence), tied to trial NCT07596784. That trial is in Phase 3 and currently recruiting, studying Generalized Myasthenia Gravis. It appears across 3 tracked trials in the CSA sample.
Next catalyst
Trial & sponsor
Trials for ravulizumab in the CSA sample
| Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|
| NCT05644561 | Phase 3 | Active, not recruiting | 2026-07-15 | Experimental | Alexion Pharmaceuticals, Inc. | Generalized Myasthenia Gravis; gMG |
| NCT07596784 catalyst | Phase 3 | Recruiting | 2027-08-17 | Experimental | Alexion Pharmaceuticals, Inc. | Generalized Myasthenia Gravis; gMG |
| NCT07024563 | Phase 3 | Recruiting | 2028-11-29 | Experimental | Alexion Pharmaceuticals, Inc. | IgAN; IgAVN; Immunoglobulin A Nephropathy; Immunoglobulin A Vasculitis Associated Nephriti… |
Each trial links to its ClinicalTrials.gov record; primary completion dates are as registered there.
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This page is one record from the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 → More AZN catalysts